Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

With two new lawsuits, Eli Lilly (NYSE: LLY) has escalated its legal campaign against the makers of unauthorized versions of ...

The combination met its primary endpoint of percent weight loss following an 8-week treatment period.

In the new analysis of data from the SUMMIT trial, researchers focused on patients with obesity, chronic kidney disease and heart failure with preserved ejection fraction because they commonly have ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

Human Heat Tolerance Lower Than Previously Believed: Study FindsA study from the University of Ottawa’s Human and ...

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Hims & Hers Health (NYSE: HIMS) stock labored mightily on Wednesday, but in the end, it couldn't top the benchmark S&P 500 ...

Meghan Trainor has revealed she has Mounjaro to thank for her new look alongside diet and exercise but she's not the only one ...

Dr Toni Hazell discusses some difficult scenarios when prescribing contraception, starting with the woman who has obesity ...